ROCKVILLE, Md. , Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md. , Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc.

Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow ROCKVILLE, Md. , Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas

ROCKVILLE, Md. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc.

ROCKVILLE, Md. , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate

ROCKVILLE, Md. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate

Total revenues for the first nine months of 2021 were $420.7 million ; a 12% increase compared to $376.8 million in the first nine months of 2020 Third quarter 2021 total revenues were $148.5 million , a 4% decrease compared to $155.1 million in third quarter 2020 Strengthen Parkinson's disease

ROCKVILLE, Md. , Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial

Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversity Nearly one-in-ten – or 6.1 million children and adolescents – are affected by ADHD ROCKVILLE, Md. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Actress, host,

Acquisition of two marketed products diversifies and accelerates revenue and cash flow Expected to be significantly accretive in 2022 Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure Total consideration up to $9.10 per share.